Both companies are clear advocates of the benefits of paperless manufacturing, validation and calibration within a FDA/GxP regulated environment.
When introducing an MES solution for the manufacturing process a company benefits instantly from efficiency gains, savings in cycle times, reduction in human errors, and improved product quality. The typical payback on the investment is between 6 and 12 months.
Nicola Smart, Strategic Planning Director at CI Precision, remarked, "I am very excited about this new partnership with CMI. This extends our global reach to strategic European territories under the umbrella of CMI who are specialised market leaders in Benelux and France. Our MES system is highly complementary to CMI's existing product offering to the Pharmaceutical market and our shared values of dedicated customer service pre and post implementation, means we have strong synergies as partners."
CMI's Operations Director, Julien Scipioni, explained, "CMI is dedicated to partnerships that benefit our customers and share our commitment to providing a great customer experience and a trusted approach. We see cooperation and customer choice as critical for building long term relationships by providing exceptional customer service and improving their business through innovation and advanced manufacturing and validation technology."
